Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;18(3):59-64.
doi: 10.5797/jnet.ra.2023-0078. Epub 2024 Jan 12.

A Review of Current Flow Diverters

Kiyofumi Yamada  1 , Hirotoshi Imamura  1 , Saya Ozaki  1 , Akihiro Niwa  1 , Yuji Kushi  1 , Naoto Yamada  1 , Taichi Ikedo  1 , Eika Hamano  1 , Hisae Mori  1 , Koji Iihara  1 , Shinichi Yoshimura  2 , Hiroharu Kataoka  1
Affiliations
Review

A Review of Current Flow Diverters

Kiyofumi Yamada et al. J Neuroendovasc Ther. 2024.

Abstract

Flow diverter (FD) devices are new-generation stents placed in the parent artery at the aneurysmal neck to obstruct intra-aneurysmal blood flow, thus favoring intra-aneurysmal thrombosis. In Japan, about eight years have passed since health insurance approval was granted for FD devices, and FD placement to treat aneurysms has become widespread. Treatment indications have also been expanded with the introduction of novel devices. At present, three types of FD (Pipeline, FRED, and Surpass Streamline) are available in Japan. This report represents a compilation of available FD technologies and describes the current consensus on this treatment.

Keywords: flow diverter; intracranial aneurysm; neurointerventional surgery.

PubMed Disclaimer

Conflict of interest statement

Yoshimura has received lecturer fees from Stryker, Medtronic, Johnson & Johnson, Kaneka, Terumo, Biomedical Solutions, Boehringer-Ingelheim, Daiichi Sankyo, Bayer, and Bristol-Meyers Squibb.Yoshimura has received research grants from Stryker, Siemens Healthineers, Bristol-Myers Squibb, Sanofi, Eisai, Daiichi Sankyo, Teijin Pharma, Chugai Pharmaceutical, HEALIOS, Asahi Kasei Medical, Kowa, and CSL Behring. Imamura has received lecturer fees from Stryker, Medtronic, Johnson & Johnson, Terumo, Daiichi Sankyo, and Asahi Intec. Yamada has received a research grant from Terumo Life Science Foundation. The other authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1. FDs available in Japan. (A) Pipeline (courtesy of Medtronic). (B) FRED (courtesy of Terumo). (C) Surpass Streamline (courtesy of Stryker). FD: flow diverter
See this image and copyright information in PMC

References

    1. Chalouhi N, Zanaty M, Whiting A, et al. . Safety and efficacy of the Pipeline Embolization Device in 100 small intracranial aneurysms. J Neurosurg 2015; 122: 1498–1502. - PubMed
    1. Wakhloo AK, Lieber BB. The beginnings of flow diversion: a historical review. In: Park M Taussky P Albuquerque FC et al.., eds. Flow diversion of cerebral aneurysms. New York: Thieme, 2018.
    1. Dandapat S, Mendez-Ruiz A, Martínez-Galdámez M, et al. . Review of current intracranial aneurysm flow diversion technology and clinical use. J NeuroInterv Surg 2021; 13: 54–62. - PubMed
    1. Kallmes DF, Ding YH, Dai D, et al. . A new endoluminal, flow-disrupting device for treatment of saccular aneurysms. Stroke 2007; 38: 2346–2352. - PubMed
    1. Ishii A. Advantages and disadvantages of flow diverter treatment for cerebral aneurysms. Jpn J Neurosurg 2022; 31: 98–106. (in Japanese)